- Home
- TOVX vs CHEK Comparison
TOVX vs CHEK Comparison
Compare TOVX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- CHEK
- Stock Information
- Founded
- TOVX 2001
- CHEK 2004
- Country
- TOVX United States
- CHEK Israel
- Employees
- TOVX N/A
- CHEK N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- TOVX Health Care
- CHEK Health Care
- Exchange
- TOVX Nasdaq
- CHEK Nasdaq
- Market Cap
- TOVX 3.8M
- CHEK 4.3M
- IPO Year
- TOVX 2006
- CHEK 2015
- Fundamental
- Price
- TOVX $0.43
- CHEK $0.77
- Analyst Decision
- TOVX Hold
- CHEK
- Analyst Count
- TOVX 1
- CHEK 0
- Target Price
- TOVX N/A
- CHEK N/A
- AVG Volume (30 Days)
- TOVX 1.6M
- CHEK 19.6K
- Earning Date
- TOVX 08-12-2025
- CHEK 08-14-2025
- Dividend Yield
- TOVX N/A
- CHEK N/A
- EPS Growth
- TOVX N/A
- CHEK N/A
- EPS
- TOVX N/A
- CHEK N/A
- Revenue
- TOVX N/A
- CHEK N/A
- Revenue This Year
- TOVX N/A
- CHEK N/A
- Revenue Next Year
- TOVX N/A
- CHEK N/A
- P/E Ratio
- TOVX N/A
- CHEK N/A
- Revenue Growth
- TOVX N/A
- CHEK N/A
- 52 Week Low
- TOVX $0.40
- CHEK $0.56
- 52 Week High
- TOVX $7.37
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- TOVX 33.63
- CHEK 45.27
- Support Level
- TOVX $0.43
- CHEK $0.71
- Resistance Level
- TOVX $0.46
- CHEK $0.77
- Average True Range (ATR)
- TOVX 0.04
- CHEK 0.03
- MACD
- TOVX 0.02
- CHEK -0.00
- Stochastic Oscillator
- TOVX 15.54
- CHEK 46.23
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.